You could be eligible to participate in the SSAD clinical trial, to find out if the experimental drug is safe and effective in treating people with Sjögren’s Syndrome.
The trial is being sponsored by Elli Lilly and Company
Visit www.clinicaltrials.gov to learn about this study
Identifier: NCT02614716
What the study consists of:
- A screening that will be completed in 2 visits to review your medical history and determine if you are eligible to participate
- A treatment phase of 16 weeks duration
- Visits occur at every 2 or 4 weeks
- A post-treatment follow-up phase of 12 weeks
- The study is expected to last 28 weeks
Phase: 1
Study Type: Interventional
Study Design: Randomized
Principal Investigator:
Thomas Grader-Beck, MD, PhD
Study Visit Location:
The Johns Hopkins Jerome L. Greene Sjögren’s Syndrome Center
Johns Hopkins Bayview Medical Center
Baltimore, MD
For more information contact:
Ana Manzano
Research Program Coordinator
Telephone: 410-550-6492